All In Biotech

Drug Trial Radar · NCT07124559

A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Jun 26, 2028

Study completion Nov 15, 2028

Sponsor

Sponsor type
NIH
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, up to 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB). The study will take place at multiple locations and children under 13 years old will be divided into two groups: one group will include children without HIV, and the other group will include children with HIV who are on antiretroviral treatment. Up to 144 children will participate, and participants in each group will be followed for 24 weeks.

Conditions

  • Tuberculosis

Interventions

  • RifapentineDrug

    Dispersible Tablet administered orally

  • IsoniazidDrug

    Dispersible Tablet administered orally

  • DolutegravirDrug

    Tablets and Tablets for oral suspension administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma concentration of Rifapentine (RPT) at specified time points among children with and without HIVTime frame: Through Day 28
  2. Area Under the Curve (AUC)(0-inf) of RPTTime frame: Through Day 28
  3. Maximum serum concentration (C(max)) of RPTTime frame: Through Day 28
  4. Half-life (t1/2) of RPTTime frame: Through Day 28
  5. Apparent oral clearance (CL/F) of RPTTime frame: Through Day 28
  6. Apparent oral volume of distribution (V/F) of RPTTime frame: Through Day 28
  7. Absorption rate (ka) of RPTTime frame: Through Day 28
  8. Trough serum concentration (C(trough)) of DTG (Cohort 2 only)Time frame: At study entry, Day 28 and Day 42
  9. CL/F of DTG (Cohort 2 only)Time frame: At study entry, Day 28 and Day 42
  10. Proportion of participants experiencing Adverse Events (AEs)Time frame: Through Day 28
  11. Proportion of participants experiencing Grade 3 or higher AEsTime frame: Through Day 28
  12. Proportion of participants experiencing Grade 2 or higher AEs assessed as related to 1HPTime frame: Through Day 28
  13. Proportion of participants experiencing Serious Adverse Events (SAEs) assessed as related to 1HPTime frame: Through Day 28
  14. Proportion of participants experiencing AEs assessed as related to 1HP that led to permanent discontinuation of the regimenTime frame: Through Day 28

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • Gaborone (Site ID: 12701)

    Gaborone, Botswana · Recruiting

  • Molepolole CRS (Site ID: 12702)

    Molepolole, Botswana · Recruiting

  • Les Centres GHESKIO (Site ID: 30022)

    Port-au-Prince, Haiti · Not yet recruiting

  • Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho CRS (Site ID: 5121)

    Kericho, Kenya · Not yet recruiting

  • Chiangrai Prachanukroh Hospital (Site ID: 5116)

    Chiang Rai, Thailand · Recruiting

  • Siriraj Hospital, Mahidol University NICHD CRS (Site ID: 5115)

    Bangkok, Bangkoknoi, Thailand · Not yet recruiting

  • Baylor-Uganda CRS (Site ID: 31798)

    Kampala, Uganda · Recruiting

  • MU-JHU Research Collaboration (MUJHU CARE LTD) CRS (Site ID: 30293)

    Kampala, Uganda · Recruiting

  • St Mary's CRS (Site ID: 30303)

    Chitungwiza, Zimbabwe · Not yet recruiting

  • Harare Family Care CRS (Site ID: 31890)

    Harare, Zimbabwe · Not yet recruiting

  • Seke North CRS (Site ID: 30306)

    Seke North, Chitungwiza, Zimbabwe · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.